Phenylpropanolamine
Overview of Phenylpropanolamine
Phenylpropanolamine (PPA) is a sympathomimetic agent used as a decongestant and appetite suppressant. It is a member of the phenethylamine class and is structurally related to ephedrine and amphetamine.
Pharmacology
Phenylpropanolamine acts primarily as an alpha-adrenergic receptor agonist, leading to vasoconstriction and decreased nasal congestion. It also has some activity as a beta-adrenergic receptor agonist, which contributes to its effects on appetite suppression.
Medical Uses
Phenylpropanolamine was commonly used in over-the-counter cold medications and weight loss products. It was effective in reducing nasal congestion and suppressing appetite.
Safety and Regulation
In the early 2000s, concerns about the safety of phenylpropanolamine led to its withdrawal from the market in many countries. Studies indicated an increased risk of hemorrhagic stroke in women using the drug. As a result, the U.S. Food and Drug Administration (FDA) issued a public health advisory in 2000, recommending that consumers not use products containing phenylpropanolamine.
Current Status
Phenylpropanolamine is no longer available in the United States and many other countries for human use. However, it is still used in veterinary medicine, particularly for the treatment of urinary incontinence in dogs.
Mechanism of Action
Phenylpropanolamine works by stimulating the release of norepinephrine and dopamine from nerve terminals, which leads to increased adrenergic activity. This results in vasoconstriction and reduced blood flow to the nasal passages, alleviating congestion.
Side Effects
Common side effects of phenylpropanolamine include increased heart rate, elevated blood pressure, anxiety, dizziness, and insomnia. Due to its stimulant effects, it can also lead to tachycardia and hypertension.
History
Phenylpropanolamine was first introduced in the 1930s and became widely used in the 1970s and 1980s. Its popularity declined after safety concerns emerged, leading to regulatory actions in the 1990s and 2000s.
Also see
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Kondreddy Naveen, Prab R. Tumpati, MD